Yumanity Therapeutics
yeast, neurodegeneration, brain drugs
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
C-KK7G
yeast, neurodegeneration, brain drugs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
AnalyticaOne - We are pleased to be part and gold sponsor... Facebook Log In AnalyticaOne's Post AnalyticaOne December 15, 2021 · Shared with Public We are pleased to be part and gold sponsor of “ Reimagining The Future OF PHARMACY & TOXICOLOGY Symposium and Workshops”. We would like to thank KSAPT management who made this event successful The conference was a great place to learn new things and to network with industry leaders We are really grateful to everyone contributed to this success. #Analyticaone #KSAPT @ksapt_meeting Dr. Maha Almazroua All reactions: 20 2 comments 5 shares Li
%PDF-1.5 %���� 74 0 obj > endobj 77 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4��
Speaker Biographies | Discovery on Target | Sept 28-Oct 1, 2026 About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery Travel Posters Post … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press 2026 Speaker Biographies Warning! Web API Url is not set for the Speaker Bios. Speaker Biographies Filter by: Last Name Organization Program Clear Filters ‹ › × Chris Adams, CEO, Andarix Pharmaceuticals CEO Andarix Pharmaceuticals Christopher P. Adams is a seasoned life sciences entrepreneur and CEO with over … research and biomarker discovery. Today, Gali leverages this diverse toolkit to apply proteomics toward unlocking next-generation therapeutic opportunities in induced proximity modalities. Novel Drug Modalities Jordi Bach, PhD, Principal Scientist, Small Molecules Discovery & Dev, Almirall SA Principal Scientist Almirall SA Jordi Bach is a Principal Scientist in the Small Molecules Discovery & Development Department at Almirall. A synthetic organic chemist by training, he obt … . He is a 2021 recipient of the American Chemical Society’s Hero of Chemistry award for his leadership role in the discovery of Lorbrenaâ„¢ a macrocyclic inhibitor of mutant ALK kinase for the treatment of NSCLC. Novel Drug Modalities Todd Bayne, JD, Attorney, Intellectual Property, Medler Ferro Woodhouse & Mills PLLC Attorney Medler Ferro Woodhouse & Mills PLLC Todd Bayne Jr. is an Associate Attorney with Medler Ferro Woodhouse and Mills based in Northern Virginia, and foc … ional and high-quality potential clinical assets. He completed his postdoctoral fellowship at the Joslin Diabetes Center at Harvard University. He received PhD and MS degrees in pharmacology, cellular and molecular biology from Universite Nice-Sophia Antipolis, France. Innovative Discovery Technologies Shruthi Bharadwaj, PhD, Technical Staff, MIT
Yumanity Therapeutics Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Focus Yumanity Therapeutics specializes in developing disease-modifying therapies for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS, presenting opportunities for suppliers of advanced biotech research tools, chemical compounds, and protein analysis technologies. Recent Collaborations The company's partnership with Janssen Medical Cloud and grants from the Michael … 2022 | www.marketscreener.com Yumanity receives financing of $500K in research grant. Yumanity Therapeutics has been awarded a $500,000 research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help accelerate testing of an investigational Parkinson’s disease therapy, YTX-7739. Jan 13, 2022 | parkinsonsnewstoday.com The Michael J. Fox Foundation invests into Yumanity $500K. Yumanity Therapeutics has been awarded a $500,000 research grant from the M … . Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS. Targeting the underlying … 2022 | www.marketscreener.com Yumanity receives financing of $500K in research grant. Jan 13, 2022 | parkinsonsnewstoday.com The Michael J. Fox Foundation invests into Yumanity $500K. Jan 12, 2022 | parkinsonsnewstoday.com Read more news Funding & Financials $34M Yumanity Therapeutics has raised a total of $34M of funding over 4 rounds . Their latest funding round was raised on Dec 15, 2020 in the amount of $34M . $1M $10M Yumanity Therapeutics 's revenue is estimate
Speaker Biographies About About Us FAQ Drug Discovery Chemistry Europe Agenda Programs Search Agenda Plenary Sessions Speaker Biographies Short Courses Training Seminar Top Pharma Breakout Discussions Attendee List Testimonials On-site Networking  Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Sponsor Prospectus Current Exhibitors/Floorplan 2027 Re-sign Floorplan Exhibit Services/Schedule Lead Generation Opportunities Sponsor & Exhibitor Portal Media Partners Best of Show Awards Downloads Brochure Downloads Interviews Poste … de Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the Protein Society Irving Sigal Young Investigator Award, the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry, the ASBMB Merck Award, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences. Stephen Fesik, PhD, Professor of Biochemistry, Pharmacology, and Chem … of Directors. His three awards from Abbott include Researcher of the Year Team Award (2008). He has also received the NIH Director's Pioneer Award (2010), and honors from numerous academic societies, the most recent being the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2012). Protein-Protein Interactions Jark Böttcher, Principal Scientist, Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG Jark Böttcher is currently working a … mic education and service towards talented scholars yielded him the Paul Harris Fellowship by the Rotary Foundation in 2014. Passionate about country life he is an eager skier happily married with two children: one baby-boy who keeps him busy with rugby over the weekends and one baby-girl who keeps him awake most of the nights. Andrew G. Cole, Ph.D., Research Fellow, Medicinal Chemistry, Arbutus Biopharma, Inc. Andrew Cole has over 20 years of drug discovery experience in the … other postdoc with UCB in Slough. This project was focused on demonstrating the application of molecular dynamics in PPI drug discovery. I have now been at UCB for more than 6 years and in this time we have developed a series of approaches for understanding early stage druggability of PPI targets. Artem Evdokimov, PhD, CSO, HarkerBIO Kamyar Hadia
Ultragenyx cuts jobs as it seeks path to profit in 2027 | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our … also said the Food and Drug Administration has once again rejected its approval application for a gene therapy for a rare degenerative disorder based on manufacturing concerns. Analysts from Leerink Partners and TD Cowen reduced their share price targets based on the longer approval timelines for the gene therapy and other pipeline assets. Shares fell by as much as 11% Friday morning. Dive Insight: Ultragenyx has proven itself successful when it comes to getting rare disease
%PDF-1.7 %���� 1 0 obj >/Metadata 1844 0 R/ViewerPreferences 1845 0 R/PageLabels 1846 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��X[k�F~_��0�Ia�s.s�E`��!�@��P�PB꧴4���3�FZ��U6Ʋ������Oj���px��Lש�ǃ�g�1ڤ���r��GT_?o7�����n ����'PQG����n@��Z������Ȫw ����� X�m}�s�"���G� W���@���} w8��j}������d�luyM��i̬-�&2��.WSp�!ZvZ�%@P�a i�4����x(eG� J��¡�n��u�u6��n��k��;�1���:�s S� ��fd"mhA�� _[?�Ʊ��8k�q��V�� �#M"�� �"I*$�� … N_�o�_^�=K�C0YD��5��+�����Fc _���%�Cv���Z^�R���� b�Q0Ec�@a��e�;J�z�I�hkj��rfP� �{ �CS����O?#>�;��Tiu�9�[ �_?�[��\|q���m��g���D�����Y�����J?�1 �7�M��CΉ�a��`@o�5��V�Z56��ɤT� ��� ^��B���.�P���� @���� ����cE�Y�άWv��\��� ���|�i��D�-+gTg�FG��ě� v(F�S�oq��~����'��䶂Zm��3��O>?�е�h�lm1�Ə do��u�҃EpHε&�w'7$�g ���G@�>��W�q���%��v��j��3�owu��^-��,�nҔw��y|�g~G��9��XAA\�����p�ċx�A���,1 �;���q��Vא?������ SQ��B��k���O>!��Y���Yx�RS�\ �BA>�T��xv��Q=��ʧ … 跂t�y� \o!��uu8�^����!��$b!��*�]y�(Á�����W�|V���5o��>?�e�ۯ����[��Z�# ����c�ˆRFpk����~*�[{k_�����(_�k *��pQ>�[��k2����ˊ����e��j�=��#G� =8�}�����>61Vu�D�w��$� �[�� Ѿ �kM��b�n�����n���NX�=IbIoS_$����W�:�4 �W� }b�[�M����gYn���+V� ֧��\$��4����vq�@ �I����Gx� �����7Ï�E�h�%���R�/b�gqجh�wwf"�ɿ�����Z������9�k=���q$����� ���i�)㼸E[�N��۫����_�T��]�=B�1{B,j ��;cӊ� m=zV�>���टvd�IJl��� �7� ����v�[s;fE � )���mC�9������t� M*�Y�o �ѧk}� ߓ($�6�A �Ҵ
REGENERON PHARMACEUTICALS, INC. - PRE 14A false 0000872589 PRE 14A 0000872589 2024-01-01 2024-12-31 0000872589 2023-01-01 2023-12-31 0000872589 2022-01-01 2022-12-31 0000872589 2021-01-01 2021-12-31 0000872589 2020-01-01 2020-12-31 0000872589 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryC … f other than the Registrant)   Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.   PRELIMINARY PROXY MATERIAL - SUBJECT TO COMPLETION   PLEASE VIEW OUR 2024 RESPONSIBILITY REPORT   regeneron.com/2024RR   Regeneron by the Numbers   13 medicines approved in the United States or other … Drug Administration (“FDA”) recently accepted our Biologics License Application (“BLA”) for linvoseltamab in this indication, with a target action date of July 10, 2025, and we are on track for a potential approval in the EU in the second quarter of 2025. We also achieved a significant milestone with odronextamab (our CD20xCD3 bispecific antibody) by marking the first regulatory approval from our bispecific antibody platform. Odronextamab was approved … Independence 20 Board Committees 20 Compensation of Directors 24     PROPOSAL No. 1 Election of Directors 27     Corporate Governance 28 Governance Overview 28 Board Governance 29 Board Structure and Proposed Board Declassification 29 Board Meetings and Attendance of Directors 29 Director Refreshment Philosophy 30 Procedures Relating to Nominees; Board Succession Planning 31 Director Onboarding 32 Board and Committee Self-Assessments 32 Board Leadership 3 … nt Registered Public Accounting Firm 55 Audit Committee Report 56     PROPOSAL No. 2 Ratification of Appointment of Independent Registered Public Accounting Firm 56     Compensation-Related Matters 57 Compensation Discussion and Analysis 57 Our Named Executive Officers 57 Executive Summary 58 Introduction to Our Compensation P
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BIO18: Merck's Ebola lessons; New Jersey vies for biotech jobs | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences
Thank you to all who... - CASSS - Sharing Science Solutions Facebook Log In CASSS - Sharing Science Solutions's Post CASSS - Sharing Science Solutions February 24 · Shared with Public Thank you to all who participated in the Exhibitor Webinar this morning with BioPharmaSpec. We look forward to seeing you next time! #CASSS #CASSSWebinar #biopharmaceuticals #biotechnology Like Comment
Novartis to cut 2,500+ jobs in the UK and Switzerland | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our br
Steve Jobs’ son raises $200M for cancer-focused venture fund | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore … article from Dive Brief Steve Jobs’ son raises $200M for cancer-focused venture fund Yosemite aims to separate itself from other investors by focusing on both early-stage startups and charitable grants for scientists in academic labs. Published Aug. 2, 2023 Gwendolyn Wu Senior Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google Dan McHugh, formerly an investor with Emerson Collective, is now part of the team at Yosemite, Reed Jobs' n … and giving philanthropic grants to academic researchers through a donor-advised fund. The money for Yosemite's inaugural fund comes from a mix of endowments, healthcare institutions and family offices, including The Rockefeller University, Memorial Sloan Kettering Cancer Center and John Doerr, a Kleiner Perkins investor. Dive Insight: The San Francisco firm is a spinout from Emerson Collective, founded by Jobs’ mother Laurene Powell Jobs. Emerson makes both venture investment … ncer patients are diagnosed and treated,” said Dan McHugh, an investor with the fund. Named after the national park where Jobs’ parents met, Yosemite joins a class of new venture funds that have launched this year, including Dimension and Cure Ventures . Several established venture firms, including Medicxi , Westlake Village BioPartners and SR One , have also announced new funds in 2023. “Truly foundational technological shifts have happened in the past few years, from the fi
Year of biotech layoffs leaves industry looking for spark | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore ou … milestones like beginning clinical trials. Crossover investors , who often help fund startups en route to an IPO, pulled back. “For the companies that have already secured a seed or a Series A round and are preclinical, I think they need to find a way of identifying a lead asset and getting it into the clinic and have some initial data for investors to sink their teeth in,” said Jon Norris, managing director at banking and financial firm HSBC. In past years, those kind of com … bringing investors back in. The XBI, a closely tracked biotech exchange-traded fund, has risen by double-digits over the past month amid a flurry of big pharma deals. It jumped nearly 4% Monday as three relatively small biotech acquisitions were announced to start the JPM meeitng. Recommended Reading 5 questions facing emerging biotech in 2024 By Gwendolyn Wu • Jan. 8, 2024 Add us on Google Share Copy link Email LinkedIn X/Twitter Facebook Print License Filed Under: Bi
Where is Yumanity Therapeutics Located? HQ, Global Offices & Company Insights Products Solution Resources Pricing Login Sign up Products Intent Signals Job Changes New Hires & Promotions Past Champions Social Media Insights Competitor Insights Engagement Social Publishing Employee Advocacy Social Audience Social Selling Social AI Copilot Analytics Social Analytics Audience Analytics Competitor Watchlist Orchestration Automated Inbound Automated Outbound Social AI Agent Sales AI Agent Account Intent Scoring Multithreading Sales CRM Enrichment & Hygiene Company & Contact Search T
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trend … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis December 15, 2020 | 10 min read Twitter LinkedIn Facebook Email Print Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-m … You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Proteostasis and Yumanity expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Yumanity Contacts Investo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Novel Prodrug with Potential for ALS and Like Diseases Acquired by Startup, Yumanity Therapeutics | ALS News Today Skip to content For Healthcare Professionals Newsletter Search Search for: Search Toggle navigation Search for: Search For Healthcare Professionals About ALS Toggle menu: About ALS What is ALS? Causes and risk factors Diagnosis Symptoms Speech problems Breathing and swallowing Pseudobulbar affect Types of ALS Familial ALS Sporadic ALS Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Living with ALS Mental health Diet E … ermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer. Tags ALS/MND Drug information treatment Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment Recent Posts Nura raises $74M to support ALS trial, new nerve-protecting therapy Oral prosetin proves safe in early trial, paving way for Phase 2 Acurastem win … trials Trial of experimental ALS therapy pridopidine enrolls first participant Grant funds new ALS treatment approach targeting TDP-43 pathway Recommended reading Discussion News Nura raises $74M to support ALS trial, new nerve-protecting therapy Discussion News Oral prosetin proves safe in early trial, paving way for Phase 2 Discussion News Acurastem wins $7.5M to advance ALS treatment to clinical trials Bionews, Inc. 3 W Garden St Suite 700 Pensacola, FL 32502 Website: bio
Orrick Advises Kineta on Merger with Yumanity Therapeutics Toggle navigation People Practices Insights Insights Technology & Innovation Orrick Tech Studio Energy & Infrastructure Finance Life Sciences & HealthTech Litigation & IP Strategic Advisory & Government Enforcement (SAGE) All Insights Featured Tariff Watch AI Law Center Online Safety Law Center Life Sciences Venture Capital Quarterly Report Channels Podcasts Events Careers About About About Us News Locations Innovation AI Adoption @Orrick Alumni Our Culture Veterans' Legal Career Fair Pro Bono Inclusion & Belonging Responsible Business … & Infrastructure Finance Life Sciences & HealthTech Search entire site Submit Search entire site Home News Orrick Advises Kineta on Merger with Yumanity Therapeutics Facebook Twitter Linkedin Orrick Advises Kineta on Merger with Yumanity Therapeutics June.06.2022 We advised Kineta, Inc., a private immuno-oncology company, on its definitive agreement to merge with Yumanity Therapeutics, a clinical-stage biopharmaceutical company dedicated to accelerating the revolutio … the net proceeds of the proposed merger and the PIPE financing are expected to fund the further development of Kineta’s immuno-oncology portfolio. The Orrick team advising Kineta was led by Blake Ilstrup , Hari Raman and Albert Vanderlaan and included Jim Bishop, Brian Blood , Kelly Mink , Nnaemeka Anyanwu, Tommy Li, Brian Kim, Michelle Lee, Peter Elias, Shana Solomon, Michael Wiesner , Sarah Schaedler , Daniel Kearney , Jennifer Criss , Daniel Kadin,
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
September 2022 – Page 38 – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Free Conference Whitepapers! Register for our Free Newsletter! Schedule Your Free Demo! Search fo … ion of the event, investors and interested parties will have the opportunity to submit questions. The Company will answer as many questions as possible during the event. A live video webcast of the Event will be available on the Events page of the Investors section of the Company’s website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year. Author [email protected] Posted on September 23
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases O … You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Proteostasis and Yumanity expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Yumanity Contacts Investo … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Translational Strategies in CNS Agenda Plenary Keynote Speaker Biographies Attendees Archives Sponsor/Exhibit Event Features and Attendee Demographics Sponsorship Opportunities Current Sponsors Current Exhibitors/Floorplan Sponsor/Exhibitor Prospectus Exhibitor Kit/ Schedule Exhibitor Testimonials FAQ Lead Generation Opportunities Media Media Partners Downloads Brochure Downloads Travel Travel Information Health and Safety Posters Submit a Poster Poster Titles Register Search 2017 Archived Content OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | SHORT COURSES | TRAINING SEMINARS The CNS industry has
Careers - IO Biotech About Overview News Careers Science Our Science Programs T-win Posters & Publications Pipeline Patients Investors Contact Careers Ignite a New Way Forward. Our people underpin what’s possible. They are the backbone of our business and the future. Careers Ignite a New Way Forward. Our people are the backbone of our mission as we co-create a future of new possibilities for people with cancer. What Does it Take to Shatter Cancer? At IO Biotech, we are a diverse team of industry leaders completely reimagining the possibilities of immunotherapy. Our drive to shatter existi … ew way forward with the goal to improve patient outcomes in unprecedented ways. Apply Now EMPLOYEE SPOTLIGHT “As a part of the R&D team, I enjoy collaborating with my dedicated coworkers to reach a better understanding of cancer and how our treatment platform can benefit real-world patients in the future. Being part of such an innovative and high-paced environment is motivating me to grow professionally.” Inés Lecoq Molinos, M.Sc. Industry Ph.D. Student EMPLOYEE SPOTLIGHT … from the University of Notre Dame and completed an NIH-sponsored post-doctoral fellowship at The Ohio State University Comprehensive Cancer Center. X Kapil Dhingra, M.D. Strategic R&D Advisor Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. He served as vice president, head of the oncology disease biology leadership team and head of oncology clinical development at Hoffmann- … e All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. X Helen Collins, M.D. Member Dr. Collins has served on our board of directors since November 2023. She is currently the Chief Medical Officer at Enliven Therapeutics. Prior to Enliven, she served as Chie … earned her MD from Johns Hopkins University School of Medicine, completing her residency at Johns Hopkins Hospital and oncology fellowship at Stanford University School of Medicine, and her BA from Bryn Mawr College. X Member Dr. Collins has served on our board of directors since November 2023. She is currently the Chief Medical Officer at Enliv
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
One-On-One With Tony Coles CEO Of Yumanity Therapeutics Get more Life Science Leader insight with our FREE newsletter. sign me up Log In or Subscribe Home Magazine Past Issues Digital Edition Articles Executive Interviews Companies To Watch Where Are They Now Industry Leader CEO Corner Ask The Board Key Topics Clinical Trials Finance-Funding Outsourcing Regulatory Research & Development Business of Biotech Podcast Magazine Article | September 3, 2018 One-On-One With Tony Coles, CEO Of Yumanity Therapeutics Source: Life Science Leader By Rob Wright , Chief Editor, Life Science Leader Follow
Open Letter 2.0 - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align Summit Partneri … st with career advancement I will also commit to at least one of the following: Grant employees unrestricted access to their own information so that they can also keep track of goals, course corrections, and contributions to the success of the team and the organization Identify potential for biases when evaluating employee performance and advancement potential; provide tools and processes that challenge leaders to consider the value of diversity and its impact on problem-solv … Corbett CEO Entasis Therapeutics Manos Perros President & CEO Epizyme, Inc Grant Bogle President and CEO Entera Bio Adam Gridley CEO EQRx, Inc. Alexis Borisy Founder, Chairman & CEO Équilibre Samuel Waskal Chairman & CEO EuMentis Therapeutics Mark Tepper CEO Evelo Biosciences Simba Gill CEO EyePoint Pharmaceuticals Nancy Lurker President & CEO FerGene David Meek CEO Finch Therapeutics Mark Smith CEO Flexion Therapeutics Michael Clayman CEO FOG Pharmaceuticals … e Rob Brainin CEO German Accelerator Life Sciences Marc Filerman CEO Global Bio Fund Ipshita Mandal-Johnson Managing Partner Graticule Daniel Poscover CEO GreenLight Biosciences Andrey Zarur CEO Gritstone Oncology Andrew Allen CEO Groupe Axiomatech Josee Dufour CEO Halloran Consulting Group Laurie Halloran President & CEO Harbinger Health Stephen Hahn CEO Harbor Clinical Ann Conner President HealthScape LifeSciences LLC Helene Clayton-Jeter Founder & CEO Hiller
Yumanity Therapeutics, INC. (YMTX) Insider Trading Skip to content InsiderTrades SIGMA Analysis Recommendations TOP Basket NEW Terminal NEW Companies Executives Performance Blog GB EN GB EN Insiders Trades Sigma InsiderTrades SIGMA Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta. FR US DE CH GB CA IT ES NL BE NO FI DK AU AT IE KR IN JP HK + 8 markets Product Recommendations Terminal Companies Insiders Performance Backtest Compare Discover Markets Sectors Top movers Leaderboard Clusters Heatmap Archive Resources Methodology How it works Glossar
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Yumanity Therapeutics Inc. (Nasdaq: YMTX) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 114 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Insid
Proteostasis Therapeutics Merges With Yumanity Therapeutics Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About CF Toggle menu: About CF What is cystic fibrosis? Symptoms Diagnosis Causes and inheritance Types of CFTR mutations Treatment Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Living with CF Tips for preventing reflux Airway clearance techniques Heat and humidity tips Handling cold weather Traveling with CF Upper and lower RTIs CF and GERD Menopause News Community Toggle menu: Community Col
A... - The Stiff Person Syndrome Research Foundation Facebook Log In The Stiff Person Syndrome Research Foundation's Post The Stiff Person Syndrome Research Foundation 2d · Shared with Public A heartfelt thank you to Kedrion Biopharma for their generous sponsorship of the 2026 SPS Symposium! Their support helps make events like this possible and reflects their commitment to patients living with rare conditions. We are grateful for their partnership! #CollaborateInnovateCure All reactions: 6 1 share Like Comment
EX-99.2 4 d141599dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 YUMANITY MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Explanatory Note: On December 22, 2020, pursuant to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of August 22, 2020 and as amended on November 6, 2020, by and among Yumanity Therapeutics, Inc. (formerly known as Proteostasis Therapeutics, Inc.) (the “Company”), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) (“Yumanity”) and Pangolin Merge … ber 30, 2020, Yumanity expects that its existing cash and cash equivalents will fund its operating expenses, capital expenditure requirements and debt service payments into the third quarter of 2021. Yumanity has based this estimate on assumptions that may prove to be wrong, and Yumanity could exhaust its available capital resources sooner than it expects. See “—Liquidity and Capital Resources.” Beyond that point, Yumanity will need to raise additional capital … ber 30, 2020, Yumanity expects that its existing cash and cash equivalents will fund its operating expenses, capital expenditure requirements and debt service payments into the third quarter of 2021. Yumanity has based this estimate on assumptions that may prove to be wrong, and Yumanity could exhaust its available capital resources sooner than it expects. COVID-19 In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date, t … pon acceptance by the Small Business Association of Yumanity’s forgiveness application. If and when the loan forgiveness becomes probable, Yumanity will recognize income for debt extinguishment. Funding Requirements Yumanity expects its expenses to increase substantially in connection with its ongoing activities, particularly as it advances the preclinical activities and clinical trials of its product candidates in development. In addition, Yumanity expects to incur addi … bsp;30, 2020, Yumanity expects that its existing cash and cash equivalents will fund its operating expenses, capital expenditure requirements and debt service payments into the third quarter of 2021. Yumanity has based this estimate on assumptions that may prove to be wrong, and Yumanity could exhaust its available capital resources sooner than i
Proteostasis Therapeutics Enters Merger Agreement With Yumanity Therapeutics // Cooley // Global Law Firm Skip to main content Contact News Events Alumni Sign up About People Services Insights Diversity Careers Geographies Press Release Proteostasis Therapeutics Enters Merger Agreement With Yumanity Therapeutics Combined companies to leverage common scientific expertise to combat neurodegenerative diseases August 25, 2020 Share Share on LinkedIn Share on X Share on Facebook Share with Email Boston – August 25, 2020 – Cooley advised Proteostasis Therapeutics (PTI) on its agreement t
Phenotypic Screening and Chemical Biology Agenda Plenary Keynote Speaker Biographies Attendees Archives Sponsor/Exhibit Event Features and Attendee Demographics Sponsorship Opportunities Current Sponsors Current Exhibitors/Floorplan Sponsor/Exhibitor Prospectus Exhibitor Kit/ Schedule Exhibitor Testimonials FAQ Lead Generation Opportunities Media Media Partners Downloads Brochure Downloads Travel Travel Information Health and Safety Posters Submit a Poster Poster Titles Register Search 2017 Archived Content OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | SHORT COURSES | TRAINING SEMINARS Chemical bi
Kineta Completes Reverse Merger with Yumanity Therapeutics --> Accessibility: Skip TopNav Kineta Completes Reverse Merger with Yumanity Therapeutics Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 December 19, 2022 06:30 ET | Source: Kineta, Inc. Kineta, Inc. SEATTLE, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Th … st immunotherapy to address the problem of exhausted T cells and is planning to submit an Investigational New Drug application (IND) in the first half of 2024. “Closing the reverse merger with Yumanity and the PIPE financing round provides Kineta with the capital necessary to advance our lead program, KVA12123, into clinical development in cancer patients,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “We remain on track to report interim safety and efficacy … ineta’s clinical trials; (x) the timing of any planned investigational new drug application or new drug application; (xi) the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; (xii) the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; (xiii) Kineta’s commercialization, marketing and manufacturing capabilities and strategy; (xiv) Kineta’s ability to identify additional product candidat
Eight MA Companies Named to Fierce 15 - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link … 015 Fierce 15 winners this morning. The Fierce 15 is a hotly anticipated annual award that recognizes the 15 most promising private biotech companies in the world. The award celebrates the spirit of being "fierce," championing innovation and creativity, even in the face of intense competition. “With eight Commonwealth innovators included, Massachusetts has the largest representation on this year’s Fierce 15 list,” said Robert K. Coughlin, Pre … degenerative diseases caused by protein misfolding. Founded in December 2014 by award winning protein folding expert, Susan Lindquist, Ph.D., and renowned biotech industry leader, Tony Coles, M.D., Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrop
Yumanity Therapeutics Announces Definitive Agreements for --> Accessibility: Skip TopNav Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions June 06, 2022 06:30 ET | Source: Yumanity Therapeutics Inc Yumanity Therapeutics Inc Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction tha … the net proceeds of the proposed merger and the PIPE financing are expected to fund the further development of Kineta’s immuno-oncology portfolio. Upon closing of the proposed transaction, Yumanity Therapeutics, Inc. will be renamed Kineta, Inc., and will be headquartered in Seattle, Washington. Shawn Iadonato, Ph.D. will serve as Chief Executive Officer and Craig Philips will serve as President of the combined company. The merger agreement provides that the Board of Directo
Yumanity Therapeutics - Wakefly Skip to content what we do who we are insights portfolio news contact what we do who we are insights portfolio news contact Yumanity Therapeutics Medical Site Migration , Web Redesign WordPress Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Home » Portfolio » Yumanity Therapeutics Project Overview Yumanity Therapeutics contracted Wakefly to plan, design and implement their new websit
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers April 22, 2021 | 9 min read Twitter LinkedIn Facebook Email Print YTX-7739 is Yumanity’s lead product candidate in c … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Kineta Completes Reverse Merger with Yumanity Therapeutics – Kineta Inc. | Kineta LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User
YUMANITY THERAPEUTICS, INC. H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support YUMANITY THERAPEUTICS, INC. H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 1 Total Filings 2021-Presen
Yumanity, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 15 Feb 2026 Yumanity, Inc. Subsidiary Company | 2014 | Massachusetts, United States | www.yumanity.com Subsidiary Company | 2014 | Massachusetts, United States | www.yumanity.com Last update 15 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Neoplasms Other Diseases Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Tec … proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders, expected to initiate as early as 2H 2026 Doug Williams, Ph.D., to become Board Chair, and Dan Tardiff, Ph.D., elevated to Chief Scientific Officer CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company devel … placement. CAMP4 intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its SYNGAP1 program, working capital, and general corporate purposes. “With this financing we are well positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “This investment marks a critical milestone as we continue our mission … age Capital Management LP, Trails Edge Capital Partners and the SynGAP Research Fund. Leerink Partners is acting as lead placement agent for the financing. Piper Sandler & Co., Cantor Fitzgerald, and Wedbush & Co. are acting as co-placement agents for the financing. Board and Management Changes: Dr. Williams joined the CAMP4 Board of Directors in March 2025 and brings extensive life science leadership to CAMP4, having contributed to the development of several transformative d … years later, despite raising $540 million through an initial public offering to fund the late-stage trials of izokibep across multiple indications, Acelyrin ultimately decided to cease investment in the drug. Izokibep achieved the primary endpoint in a Phase III clinical trial for the treatment of hidradenitis suppurativa (HS), demonstrating a 33
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement | News & Events | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Press Release August 24, 2020 Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement Professionals Stuart M. Cable John T. Haggerty Catherine Magazu View PDF Share The Life Sciences team advised Y … va Launches AHZANTIVE® Aflibercept Biosimilar in Europe Alert June 22, 2026 SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies Alert June 18, 2026 Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates Insight June 18, 2026 Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations Big Molecule Watch June 16,
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Se … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2 November 10, 2021 | 11 min read Twitter LinkedIn Facebook Email Print Yumanity Therapeutics is a clinical … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Yumanity Therapeutics, Inc. (YMTX) 10K Annual Reports & 10Q SEC Filings HOME LOGIN PREMIUM SEC FILINGS FREE TRIAL API FOOTNOTED STOCK SCREENERS EARNINGS TRENDING INSIDER TRADING MANAGER PORTFOLIOS SENTIMENT ANALYSIS LATE NT SEC FILINGS Yumanity Therapeutics, Inc. (YMTX) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021 Home SEC Filings Yumanity Therapeutics, Inc. (YMTX) 10-K Annual Report Thu Mar 24 2022 SEC Filings YMTX Valuations Intrinsic Value Financial Stability Financial Ratios Insider Trades Manager Portfolios Historical Financials (CSV) Notif … tion (Detail) Stock/Equity-Based Compensation - Schedule Of Share-Based Payment Award Stock Options Valuation Assumptions (Detail) Stock/Equity-Based Compensation - Summary Of Restricted Stock Unit Activity And Related Information (Detail) Stock/Equity-Based Compensation - Summary Of Stock Option Activity (Detail) Stock/Equity-Based Compensation - Summary Of Stock-Based Compensation Expense (Detail) Subsequent Events Subsequent Events - Additional Information (Detail) Summary
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
10-K 1 d51046d10k.htm 10-K 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller re … hich we anticipate our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements; • the potential for our business development efforts to maximize the potential value of our portfolio; • our ability to compete with other companies currently marketing or engaged in the development of treatments for the indications that we are pursuing for our product candidates; … n Agreement, we granted Merck an exclusive, worldwide license with the right to grant and authorize sublicenses, under certain intellectual property rights related to two certain undisclosed targets in connection with our ALS and FTLD programs to make, have made, use, import, offer to sell and sell compounds and products covered by such intellectual property rights. In the event that the exploitation of such compound or product would infringe during the term of the Merck Coll … .S. non-provisional patent applications, one pending international patent (PCT) application, and nineteen pending patent applications outside the U.S., which, if pursued and granted in the U.S., would be expected to expire in 2037-2040, without taking a potential patent term adjustment or extension into account, with composition of matter claims
Nikon Corporation and Yumanity Therapeutics Enter Contract for the Commission Development of Drug Discovery Assay System in Neurodegenerative Diseases | News | Nikon About Us Select your country/region. You are in our Global Site. Japan Change your location Change your location Go Close Global About Us Global Home Business Consumer Search Global Network Search keyword(s) Search Global Navigation Menu Corporate Information Corporate Information : Top Message from the CEO Philosophy & Vision Company Data Businesses Directors, Officers and Executive Fellows Nikon Group Companies Brand History … en Innovation Intellectual Property Initiatives Tech Library Stories Technology Award Nikon Research Report Close Design Design : Top About Message Works Interviews Awards News Close Sustainability Sustainability : Top Message from the President Nikon's Sustainability Business Activity Environment Society / Labor Governance Report Participation in Initiatives External Evaluations Highlight Corporate Citizenship Activities Environmental Actions at Business Facilities Sustainab … cent years. Nikon is promoting the acceleration of drug discovery and practical application of regenerative medicine by offering the BioStation CT, a cell culture observation system that utilizes live cell imaging technology *2 , which Nikon has developed in the field of biological microscopes. The company is also offering a cell quality / culturing process evaluation system for integral management of the whole cell manufacturing process. Based on consignment from drug discov … en Innovation Intellectual Property Initiatives Tech Library Stories Technology Award Nikon Research Report Design Design : Top About Message Works Interviews Awards News Sustainability Sustainability : Top Message from the President Nikon's Sustainability Business Activity Environment Society / Labor Governance Report Participation in Initiatives External Evaluations Highlight Corporate Citizenship Activities Environmental Actions at Business Facilities Investor Relations In
Tony Coles | Council on Foreign Relations Skip to content Support CFR Foreign Affairs Member Login Regions Topics Research Experts Events The Future of American Strategy Tony Coles Executive Chairman, Cerevel Therapeutics Tony Coles has served as the Cerevel Therapeutics chairperson of the board of directors since December 2018 and was previously the CEO of Cerevel from September 2019 to June 2023. Prior to joining Cerevel, Dr. Coles co-founded and served as the chairperson and CEO of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative di
Kineta Finalizes Reverse Merger with Yumanity, Secures Additional Funding | Life Science Washington Skip to content Life Science Washington An independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Toggle Mobile Navigation Menu Membership Member Benefits Membership Dues Calculator HR Connect Business Solutions Partners Events Signature Events LSW Events LSW EVS Events Community Events About Our Vision & Values Our Team Our Board of Directors Policy & Resources Diversity & Inclusion Industry Reports Policy Blog Policy Agen … immune response. In addition to KVA12123 clinical trials, the company plans to submit an investigational new drug application for T-cell treatment at the beginning of 2024. “We remain on track to report interim safety and efficacy data for KVA12123 in patients with advanced solid tumors in late 2023,” Kineta CEO, Shawn Iadonato. “We greatly appreciate the support of our investors as we continue to deliver on our mission of developing next-generation immunotherapi
Kineta Completes Reverse Merger with Yumanity Therapeutics – RLB Holdings Skip to content LinkedIn Search for: Home Our Holdings News Our Team Contact Us Search for: Kineta Completes Reverse Merger with Yumanity Therapeutics Previous Next Kineta Completes Reverse Merger with Yumanity Therapeutics Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resis … st immunotherapy to address the problem of exhausted T cells and is planning to submit an Investigational New Drug application (IND) in the first half of 2024. “Closing the reverse merger with Yumanity and the PIPE financing round provides Kineta with the capital necessary to advance our lead program, KVA12123, into clinical development in cancer patients,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “We remain on track to report interim safety and efficacy … ineta’s clinical trials; (x) the timing of any planned investigational new drug application or new drug application; (xi) the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; (xii) the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; (xiii) Kineta’s commercialization, marketing and manufacturing capabilities and strategy; (xiv) Kineta’s ability to identify additional product candidat
Humantic AI Profile for Ken Rhodes, Vice President, Research, Neuroscience, Bristol Myers Squibb Public Profile Public professional data Reveal selling playbook search picture_as_pdf share URL has been copied! in Ken Rhodes Login to view DISC. Vice President, Research, Neuroscience at Bristol Myers Squibb 📍 Cambridge, Massachusetts, United States Ken Rhodes is the Vice President of Neuroscience Research at Bristol Myers Squibb, leading the companys re-established focus on brain drugs. His extensive career includes leadership roles at Pfizer, Yumanity Therapeutics, and Biogen, consisten
Sanofi Ventures | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Sanofi Ventures Sanofi Ventures is the corporate venture capital arm of Sanofi. It invests in early-stage biotech and digital health companies of strategic interest to Sanofi, providing capital from seed through Series B and beyond while offering portfolio companies access to Sanofi expertise across science, development, regulatory, data analytics, manufacturing, market access and commercialization. The team leads financings, serves on boards, and aims to suppo
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Proteostasis Therapeutics - F-Prime Capital Skip to content F-Prime Capital People Portfolio Impact Search Home People Portfolio Life Sciences Technology Healthtech + Services Crypto Impact About Jobs Fintech Index Proteostasis Therapeutics Merged with Yumanity Therapeutics in 2020 Developing therapies targeting protein misfolding diseases. Investment Team Stephen Knight, MD Sector Life Sciences Category Therapeutics Status Public Location Cambridge, MA Initial Investment 2008 Developing therapies targeting protein misfolding diseases. Proteostasis Therapeutics is a drug discovery company deve
Portfolio | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Our Portfolio IPO / Acquired Investments Biotherapeutic Digital Health All abcuro Close Private Newton, MA www.abcuro.com Developing treatments for autoimmune and cancer indications. Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 … ence. Press releases Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Jan 10, 2022 Read More Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform. Mar 25, 2021 Read More Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health Jul 01, 2020 Read More Evidation Health and BARDA Partner on Early Warning System for COVID-19 Jun 04, 2020 Read More Evidation … erited Metabolic Disorders Jul 29, 2014 Read More Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders Jun 30, 2014 Read More Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium Jun 05, 2014 Read More Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients … eutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund Apr 09, 2020 Read More Icosavax Close Acquired Seattle www.icosavax.com Focusing on developing safe and effective vaccines against infectious diseases. Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like parti … res $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support. Feb 25, 2021 Read More Minervax Close Private Copenhagen, Denmark minervax.com Developing a prophylactic vaccine against Group B Streptococcus. Minervax is a clinical stage biotechnology company developing a prophylactic
Jacob Bell | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Deep … eached on Signal at realjacobbell.38. Get in touch Email [email protected] Submit a tip to our team 1763 articles by Jacob Bell Filter by month: Show All Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda June 26, 2026 To Wall Street, psychedelics biotechs are more teammates than rivals June 24, 2026 How Kardigan spun deal leftovers into a $400M IPO June 23, 2026 UniQure to file gene therapy for approval, reflecting major shifts at FDA June 17, 2026 A new West … lis buy, builds out immunology offerings March 31, 2026 Blackstone closes $6.3B fund for life sciences investing March 30, 2026 Otsuka picks up PTSD drug with $700M Transcend buy March 27, 2026 How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup March 24, 2026 Roche stops work on experimental SMA drug March 20, 2026 RBC: Revolution, Xenon, Arrowhead among top takeover targets March 18, 2026 With FDA go ahead, a China biotech notches a first in cell th … roscience May 1, 2025 Biohaven stock slides on withdrawal of European marketing application April 25, 2025 Bristol Myers says schizophrenia drug launch ‘off to a solid start’ April 24, 2025 Bristol Myers’ prized schizophrenia drug stumbles in testing April 23, 2025 Former Neumora CEO to lead Galapagos spinout April 22, 2025 New research kindles excitement around stem cell therapies for Parkinson’s April 16, 2025 GSK targets neurodegenerative diseases with latest licensing dea … mer’s drug Leqembi Oct. 25, 2023 BrainStorm, after setbacks, withdraws approval application for ALS drug Oct. 18, 2023 Roche is stuck on molecular glue Oct. 17, 2023 Amylyx’s ALS drug knocked back again in Europe Oct. 13, 2023 After summer slump, biotech M&A has a good week Oct. 10, 2023 NIH funds research for three experimental ALS drugs Oct
Deals | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Deep Dive … here. By Ned Pagliarulo • March 10, 2016 Wikimedia Alaska Permanent Fund betting big on biotech startups The Fund has invested over $280 million into Juno Therapeutics, Codiak BioSciences, and Denali Therapeutics. By Nicole Gray • March 4, 2016 Sanofi's generics divestment in the E.U. likely to be delayed The company is searching for a deal to sell all or some of its generics unit Zentiva, which makes Plavix and Aprovel. By Nicole
Daniel F. Tardiff, PhD | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson’s Biomarkers Prizes Understanding Parkinson's Unders … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent
Big pharma backed away from brain drugs. Is a return in sight? | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explo
Merck strikes another neuroscience deal, tapping Yumanity for 2 brain drugs | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life S
Proteostasis bows out of cystic fibrosis drugmaking through Yumanity merger | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life S
Biopharma giants Biogen & Sanofi buy into round A for Tony Coles' Yumanity | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharm
Yumanity cutting 60% of employees as it mulls possible sale | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore
424B3 1 ny20004801x9_424b3.htm 424B3 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-267127     ​ ​   PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Yumanity Therapeutics, Inc. and Shareholders of Kineta, Inc.: On June 5, 2022, Yumanity Therapeutics, Inc. (“Yumanity”), Kineta, Inc. (“Kineta”) and Yacht Merger Sub, Inc., a wholly-owned subsidiary of Yumanity (“Merger Sub”) entered into an Agreement and Plan of Merger, as may be amended from time to time (the “Merger Agreement … licit additional proxies if there are not sufficient votes in favor of Yumanity Proposal Nos. 1, 2, 3 or 4; and 8. transact such other business as may properly come before the Yumanity special meeting or any adjournment or postponement thereof. Kineta shareholders are being asked to adopt the Merger Agreement and vote in favor of any other matter necessary to consummate the transactions contemplated by the Merger Agreement. As described in the accompanying proxy statement/pro … he transactions contemplated by the Merger Agreement, (ii) approval of any proposal to adjourn or postpone a meeting of the holders of Kineta capital stock to a later date, if there are not sufficient votes for the adoption of the Merger Agreement and the transactions contemplated thereby on the date such meeting is held, and (iii) any other matter necessary to consummate the transactions contemplated by the Merger Agreement that are considered and voted upon by the … ered and voted upon by the Kineta shareholders, and (b) against any Acquisition Proposal, as defined in the Merger Agreement. The support agreements will terminate upon certain events, including any termination of the Merger Agreement in accordance with its terms. Absent termination of the Merger Agreement, holders of a sufficient number of shares of Kineta capital stock required to adopt the Merger Agreement have agreed to adopt the Merger Agreement, and no meeting of Kineta … ty Incentive Plan (the “2022 Plan”). 6. To consider and vote upon a proposal to approve, on a non-binding advisory vote basis, compensation that will or may become payable by Yumanity to its named executive officers in connection with the Transactions. 7. To consider and vote upon an adjournment of the Yumanity special meeting, if nec
Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases June 24, 2020 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Learn about the benefits of laser in treating neur Yumanity Therapeutics and Merck signed a strategic research and license deal f … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account December 05, 2022 07:30 ET | Source: Yumanity Therapeutics Inc Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval ... November 14, 2022 08:
Tony Coles's Yumanity Raises $45m To Treat Neurodegenerative Diseases Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Spotlight China Obesity AI Drug Pricing Cell & Gene Therapies Business Deals Financing Earnings Commercial Strategy Approvals & Launches Trial Results Market Access Disease Cancer Immune Disorders Cardiovascular Neurological Rare Diseases Deep Dives Interviews Data Insights Scrip Asks Disease Landscapes Focus On Asia Japan South Korea India Scrip Asia 100 Tools & Trackers Pipeline Watch Finance Watch Deal Watch Stock Watch Top Selling Dru … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window More Scrip Perspectives Scrip 100 Ranking Scrip Asia 100 Conferences Executives On The Move Pipeline Watch Terms and Conditions Opens in new window Privacy Policy Opens in new window
Tony Coles, MD - Black Economic Alliance Foundation About Overview Leadership Board Careers Research and Data Events BEA Solutions Summit CBE Contact --> Sign Up --> Donate Tony Coles, MD By Black Economic Alliance | May 28, 2018 Tony Coles, M.D., has served as the Cerevel Therapeutics chairperson of the board of directors since December 2018 and previously was also the chief executive officer of Cerevel from September 2019 to June 2023. Prior to joining Cerevel, Dr. Coles co-founded and served as the chairperson and chief executive officer of Yumanity Therapeutics, a biotechnology company foc … ch and Data Events BEA Solutions Summit CBE Contact Sign Up Sign-Up BEA PAC BEA Fund BEA Candidates --> Eric Adams Mayor, City of New York Mayor Eric Adams has served the people of New York City as an NYPD officer, State Senator, Brooklyn Borough President, and now as the 110th Mayor of the City of New York. He gave voice to a diverse coalition of working families in all five boroughs and is leading the fight to bring back New York City’s economy, reduce inequality, improve p … lopment Corporation. She also serves on the boards of the Low-Income Investment Fund, the Center for an Urban Future, Smithsonian National Portrait Gallery, Planned Parenthood Federation of America, and the Africa Center. SHENA ASHLEY Vice President, Capital One Community Impact & Investment & President, Capital One Insights Center Shena Ashley, PhD became the head of programs within the Community Impact and Investment team at Capital One and President of the Insights Center … merce and was awarded the U.S. Small Business Administration (SBA) 2017 Phoenix Award for Outstanding Contributions to Disaster Recovery by a Public Official for his leadership during the October 2015 flood, the 2018 USGLC Leading Globally Matters Locally Award & the inaugural recipient of the AIPAC Ralph Bunche Leadership Award (2018). As President of the U.S. Conference of Mayors, Mayor Benjamin established the Mayors Leadership Institute on Smart Cities at the Robert F … usinesses survive and thrive. Melissa serves as General Partner of 1863 Venture Fund, Venture Partner at NextGen Ventures and as an advisor to Reign Ventures, New Voices Foundation, as well as the Halcyon Fund. She is a board member of Ureeka, a small business platform company she co-founded and sold, as well as Eat the Change, Motley Fool Founda
Targeting Enzyme Has Potential as Parkinson’s Therapy, Yumanity Says Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Parkinson's Toggle menu: About Parkinson's What is Parkinson’s disease? Causes Diagnosis Symptoms Motor symptoms Nonmotor symptoms Types Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Exercise Diet Parkinson’s progression News Community Toggle menu: Community Awareness Month Perspectives The Bright Side – Jamie Askari The Impatient Patient – Doc Irish Living My Best L … inical trial Gene therapy strategy may ease Parkinson’s disease dyskinesia MJFF grant to fund Montara’s brain-targeting Parkinson’s treatment Recommended reading Discussion News Scenic joins LITE program to test Parkinson’s treatment approach Discussion News Bial drops Parkinson’s therapy after it fails to slow disease in trial Discussion News Parkinson’s therapy mirivadelgat selected for multi-drug clinical trial Subscribe to our newsletter Get
Yumanity's days as an independent biotech come to a close | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explo
Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases June 24, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Strategic Alliance Combines Yumanity’s Innovative Drug Disco … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Startup Yumanity Closes on $45 Million, With Biogen and Sanofi-Genzyme BioVentures Joining In - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Startup Yumanity Closes on $45 Million, With Biogen and Sanofi-Genzyme BioVentures Joining In February 10, 2016 | 3 min read Twitter LinkedIn Facebook Email Print Lukas Roth February 10, 2016 By Mark Terry , BioSpace.com Breaking News Staff Cambridge, Mass.-based Yumanity Therapeutics announc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Yumanity, Merck strike deal on medicines for neurodegenerative disease Skip to Main Content Donald Trump Eli Lilly Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Ho … [email protected] @adamfeuerstein Tags biotechnology neuroscience STAT+ To submit a correction request, please visit our Contact Us page . Trending Supreme Court ruling on Roundup points to a confusing… Supreme Court ruling on Roundup points to a confusing difference between the law and science Eli Lilly gave extraordinary obesity drug access to a… Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? BIO 2026: AI, federal p
Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease October 7, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Yumanity Therapeutics, a company focused on protecting the vitality of the mind by discovering … egeneration. This Phase 1 trial will provide important validation for the broad application of our technology to help address arguably the most important therapeutic challenges of our time.” About YTX-7739 YTX-7739 is Yumanity Therapeutics’ proprietary lead investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target that plays an important and previously unrecognized role in the neurotoxicity caused by the a-synuclein prote … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioForest Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors October 17, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Kineta, Inc., a clinical-stage biotechnology company focused on the development … , without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumst … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioForest Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors November 15, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Kineta, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigation … S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) to evaluate its VISTA blocking immunotherapy, KVA12123 (formerly referred to as KVA12.1), as a potential treatment for patients with advanced solid tumors. SEATTLE, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Kineta , Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies that address cancer immune resistance, announce … S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) to evaluate its VISTA blocking immunotherapy, KVA12123 (formerly referred to as KVA12.1), as a potential treatment for patients with advanced solid tumors. Kineta is planning to conduct a Phase 1 ⁄ Phase 2 clinical study evaluating KVA12123 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. The objectives of the study are to evaluate t … , without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except
Kineta Completes Reverse Merger with Yumanity Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Kineta Completes Reverse Merger with Yumanity Therapeutics December 19, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion … st immunotherapy to address the problem of exhausted T cells and is planning to submit an Investigational New Drug application (IND) in the first half of 2024. “Closing the reverse merger with Yumanity and the PIPE financing round provides Kineta with the capital necessary to advance our lead program, KVA12123, into clinical development in cancer patients,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “We remain on track to report interim safety and efficacy … ineta’s clinical trials; (x) the timing of any planned investigational new drug application or new drug application; (xi) the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; (xii) the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; (xiii) Kineta’s commercialization, marketing and manufacturing capabilities and strategy; (xiv) Kineta’s ability to identify additional product candidat … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect inn
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions June 6, 2022 | 13 min read Twitter LinkedIn Facebook Email Print Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for ne … the net proceeds of the proposed merger and the PIPE financing are expected to fund the further development of Kineta’s immuno-oncology portfolio. Upon closing of the proposed transaction, Yumanity Therapeutics, Inc. will be renamed Kineta, Inc., and will be headquartered in Seattle, Washington. Shawn Iadonato, Ph.D. will serve as Chief Executive Officer and Craig Philips will serve as President of the combined company. The merger agreement provides that the Board of Directo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
On the Bubble, Yumanity Announces Layoffs of 60% of Staff - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business On the Bubble, Yumanity Announces Layoffs of 60% of Staff February 17, 2022 | 2 min read | Hannah Chudleigh Twitter LinkedIn Facebook Email Print In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its fi … idate for Parkinson’s disease in November 2021, Yumanity was awarded a $500,000 grant by the Michael J. Fox Foundation for more research in Parkinson’s. But underneath, the company was struggling. Despite successful clinical trials, the Q3 2021 reports showed a $10 million net loss, compared to a net loss of $6.4 million the previous year. By December 2021, it was offering inducement grants of non-statutory stock options for purchase. By February 17, shares of the company had … arkinson’s—for which Yumanity had already submitted an Investigational New Drug Application to the U.S. Food and Drug Administration - was put on partial hold in January 2022. Apparently, pressures bottled up and have now exploded with the major restructure and layoffs. Yumanity is laying off around 26 of its 44 employees in a process that will be complete by April. The company also announced that it is exploring “strategic restructuring” options to preserve capital, includin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potential New Therapeutic Target for the Treatment of Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potential New Therapeutic Target for the Treatment of Parkinson’s Disease December 4, 2018 | 5 min read Twitter LinkedIn Facebook Email Print Results suggest inhibiting fatty acid desaturation by blocking the enzyme stearoyl-CoA de … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson’s Disease September 5, 2018 | 4 min read Twitter LinkedIn Facebook Email Print First-in-Human Trials Planned for the Fourth Quarter of 2019 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Yumanity … trength of their INDiGO platform to begin development of YTX-7739.” Evotec will apply their industry-leading INDiGO platform to support clinical development of YTX-7739. The INDiGO platform is a component of Evotec’s broad EVT Execute business strategy and accelerates drug candidates into the clinic by reducing time from nomination to IND submission to 52 weeks or less. Accelerated development is achieved by tightly integrating traditional drug development activities into a s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Yumanity Therapeutics, Inc. | Tech Launch Arizona Skip to main content Search search search Search menu Menu home Home close Close Search search Main Menu About chevron_right Inventions chevron_right Startups chevron_right Incubation chevron_right News & Events chevron_right Contact Us Utility Links Faculty & Staff Entrepreneurs & Enthusiasts Industry Students CTA Menu Submit an Invention Startup Opportunities Available Technologies Main navigation About About TLA Activity & Impact Staff Directory Commercialization Network Wildcat Investor Network Faculty Innovation Ambassadors … Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network "Fueled By Arizona" Logo Program Commercialization FAQ Incubation Incubation for Startups Incubation Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network Commercialization FAQ News & Events News Events Annual Reports Awards & Honors Fast Forward Newsletter Social Media Contact Us Home Yumanity
Yumanity Therapeutics Announces Strategic Research Collaboration & License Agreement With Merck You are using an outdated browser. Please upgrade your browser to improve your experience. SUBMISSION GUIDELINES ABOUT US BACK ISSUES MEDIA PLANNER CONTACT FREE PRINT SUBSCRIPTION Login --> --> Subscriptions Current/Back Issues/eBooks Market News & Trends Executive Interviews --> Select a Section Analytical Testing Bioavailability & Solubility Bio Platforms Drug Delivery Injection Devices Excipients Formulation Development Contract Services Bio Platforms, Exclusive Online Content, Formu … Late Stage Customization PCI’s Paul Smallman and Michelle D’Angelo explore the application and opportunities for leveraging advanced technologies in late stage customization and its potential to benefit pharmaceutical and biotech companies in gaining competitive advantage in their global supply chain. Learn More > A Guide to Aseptic Manufacturing The aseptic manufacturing process is complex with each drug candidate's unique set of challenges. Speed to market is necessary, … by WalkerTek . Don’t miss out on this exclusive content! Fill out the form and submit today Fill out the form below to access this exclusive content. --> Close this module
EX-99.1 2 d249482dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX” Initiated dosing in the Phase 1b part of our MAD trial of YMTX-7739 in patients with Parkinson’s Disease; preliminary results expected by mid-year 2021 Boston , March 31, 2021 – Yumanity Therapeutics (NASDAQ: YMTX), a cl
Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement With Merck - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions Suppliers Suppliers overv
Yumanity Therapeutics Announces $500 Million Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases | News & Events | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Press Release June 24, 2020 Yumanity Therapeutics Announces $500 Million Strategic Research Collaborati … va Launches AHZANTIVE® Aflibercept Biosimilar in Europe Alert June 22, 2026 SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies Alert June 18, 2026 Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates Insight June 18, 2026 Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations Big Molecule Watch June 16,